Press releases
- Halozyme Announces Bristol Myers Squibb Received Updated Action Date from the U.S. Food and Drug Administration for Subcutaneous Nivolumab Co-Formulated with ENHANZE®
- Halozyme to Participate in Upcoming Investor Conferences
- HALOZYME REPORTS FIRST QUARTER 2024 FINANCIAL AND OPERATING RESULTS
- Mahesh Krishnan Elected to Halozyme's Board of Directors
- Halozyme to Report First Quarter 2024 Financial and Operating Results
More ▼
Key statistics
On Friday, Halozyme Therapeutics Inc (0J2O:LSE) closed at 43.91, -4.94% below its 52-week high of 46.19, set on May 17, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | -- |
Low | -- |
Bid | -- |
Offer | -- |
Previous close | 43.91 |
Average volume | 1.33k |
---|---|
Shares outstanding | 127.27m |
Free float | 125.86m |
P/E (TTM) | 18.32 |
Market cap | 5.64bn USD |
EPS (TTM) | 2.42 USD |
Data delayed at least 20 minutes, as of May 31 2024 17:48 BST.
More ▼